The American Journal of Managed Care

Study Probes Immune Context Differences in BRAF-Mutant, Wild-Type Melanoma

Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades. The findings could lead to a better ...
News Medical

Measuring ctDNA may lead to alternative treatment options for BRAF wild-type melanoma

Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study that assessed ctDNA in the blood of patients with BRAF wild-type (BRAF ...
ascopubs.org

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study Supported by the NIH/NCI ...
The American Journal of Managed Care

Amivantamab Plus FOLFOX/FOLFIRI Demonstrates Strong, Durable Activity in mCRC

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a median progression-free survival of 9.2 months. The study highlighted notable ...
News Medical

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...